ZELNORM
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jul 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZELNORM (tegaserod) is an oral small-molecule 5-HT4 receptor agonist approved in 2002 for gastrointestinal motility disorders. It stimulates peristaltic reflex, enhances intestinal secretion, and normalizes impaired motility throughout the GI tract while moderating visceral sensitivity. The drug targets patients with functional GI conditions characterized by reduced intestinal motor activity.
LOE Approaching
As LOE approaches, the brand team is likely contracting or refocusing on lifecycle extension; limited growth opportunity remains for commercial expansion roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZELNORM offers limited career growth due to approaching LOE and minimal linked job openings. Professionals joining this product should expect to manage market contraction, generic transition, and potential brand consolidation rather than expansion.
Brand ManagerMedical Science Liaison
Worked on ZELNORM at Alfasigma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.